Gene-based Zika vaccine is safe and immunogenic in healthy adults

(NIH/National Institute of Allergy and Infectious Diseases) Results from two Phase 1 clinical trials show an experimental Zika vaccine developed by government scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is safe and induces an immune response in healthy adults. The findings will be published on Dec. 4 in The Lancet. NIAID is currently leading an international effort to evaluate the investigational vaccine in a Phase 2/2b safety and efficacy trial.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news